Evidence map›Paper›PMID 38171639›Full record

ArticleBMJ case reports2024

Disseminated tuberculosis associated with fingolimod treatment in a patient with multiple sclerosis.

Stephanie Ong, Joseph Kibbler, Gemma Maxwell, John Steer

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Histoplasmosis in a fingolimod-treated patient: case report and scoping review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Stephanie OngNeurology, Sunderland Royal Hospital, Sunderland, UK.
Joseph KibblerNewcastle University, Newcastle upon Tyne, UK joseph.kibbler@nhs.net.
Gemma MaxwellNeurology, Sunderland Royal Hospital, Sunderland, UK.
John SteerRespiratory Medicine, Northumbria Healthcare NHS Foundation Trust, North Shields, UK.
Northumbria Healthcare NHS Foundation Trust · GBSunderland Royal Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fingolimod is a sphingosine-1-phosphate receptor modulator approved as a disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (MS). A woman in her 30s was treated with fingolimod for relapsing-remitting MS. After 7 years of treatment, she presented with non-productive cough, night sweats, breathlessness and unintentional weight loss. She had a negative interferon-gamma release assay (IGRA). A high-resolution CT thorax showed innumerable miliary opacities in both lungs. Bronchoalveolar lavage was positive for

Indexed as

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingTuberculosisFemaleFingolimod HydrochlorideHumansImmunosuppressive AgentsPropylene GlycolsSphingosineFingolimod HydrochlorideImmunosuppressive AgentsPropylene GlycolsSphingosineInfectious diseasesMultiple sclerosisNeurologyTB and other respiratory infections

Identifiers

PMID38171639
PMCPMC10773306
OpenAlexW4390595242

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.